“Identification of Nafamostat and VR23 as COVID-19 drug candidates by targeting 3CL(pro) and PL(pro)"

The sudden increase in the COVID-19 epidemic affected by novel coronavirus 2019 has jeopardized public health worldwide. Hence the necessities of a drug or therapeutic agent that heal SARS-CoV-2 infections are essential requirements. The viral genome encodes a large Polyprotein, further processed by...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhowmik, Deep, Sharma, Ravi Datta, Prakash, Amresh, Kumar, Diwakar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884051/
https://www.ncbi.nlm.nih.gov/pubmed/33612858
http://dx.doi.org/10.1016/j.molstruc.2021.130094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884051/
https://www.ncbi.nlm.nih.gov/pubmed/33612858
http://dx.doi.org/10.1016/j.molstruc.2021.130094

Ejemplares similares